SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development

Developmental Dynamics

Volumn 236, Issue 2, 2007, Pages 606-612

  Van Bezooijen, Rutger L ^a   DeRuiter, Marco C ^a   Vilain, Nathalie ^b   Monteiro, Rui M ^c   Visser, Annemieke ^a   Van Der Wee Pals, Lianne ^a   Van Munsteren, Conny J ^a   Hogendoorn, Paneras C W ^a   Aguet, Michel ^b   Mummery, Christine L ^c   Papapoulos, Socrates E ^a   Ten Dijke, Peter ^a   Löwik, Clemens W G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c HUBRECHT INSTITUTE   (Netherlands)

Author keywords

BMP; Great arteries; Heart development; Outflow tract; SOST; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GLYCOPROTEIN; MESSENGER RNA; SOST PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; EMBRYO; EMBRYO DEVELOPMENT; GENE EXPRESSION; GREAT BLOOD VESSEL; HEART; HEART DEVELOPMENT; IN SITU HYBRIDIZATION; MOUSE; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL;

ANIMALS; ARTERIES; BONE MORPHOGENETIC PROTEINS; CARDIOVASCULAR SYSTEM; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC MARKERS; IN SITU HYBRIDIZATION; MICE; MUSCLE, SMOOTH; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 33846925672     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.21054     Document Type: Article

References (27)

1. Allen SP, Bogardi JP, Barlow AJ, Mir SA, Qayyum SR, Verbeek FJ, Anderson RH, Francis-West PH, Brown NA, Richardson MK. 2001. Misexpression of noggin leads to septal defects in the outflow tract of the chick heart. Dev Biol 235:98-109.
2. Bachiller D, Klingensmith J, Shneyder N, Tran U, Anderson R, Rossant J, De Robertis EM. 2003. The role of chordin/Bmp signals in mammalian pharyngeal development and DiGeorge syndrome. Development 130:3567-3578.
3. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543.
4. Bergwerff M, Verberne ME, DeRuiter MC, Poelmann RE, Gittenberger-de Groot AC. 1998. Neural crest cell contribution to the developing circulatory system: implications for vascular morphology? Circ Res 82:221-231.
5. Boot MJ, Gittenberger-de Groot AC, Van Iperen L, Hierck BP, Poelmann RE. 2003. Spatiotemporally separated cardiac neural crest subpopulations that target the outflow tract septum and pharyngeal arch arteries. Anat Rec A Discov Mol Cell Evol Biol 275:1009-1018.
6. Brade T, Manner J, Kuhl M. 2006. The role of Wnt signalling in cardiac development and tissue remodelling in the mature heart. Cardiovasc Res 72:198-209.
7. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589.
8. DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, Gittenberger-de Groot AC. 1997. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 80:444-451.
9. Eisenberg LM, Eisenberg CA. 2006. Wnt signal transduction and the formation of the myocardium. Dev Biol 293:305-315.
10. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. 2006. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5(G171V) to modulate Wnt activity. J Bone Miner Res 21:1738-1749.
11. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, Beighton P, Papapoulos SE. 2005. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392-6395.
12. Hamersma H, Gardner J, Beighton P. 2003. The natural history of sclerosteosis. Clin Genet 63:192-197.
13. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. 2000. Fate of the mammalian cardiac neural crest. Development 127:1607-1616.
14. Li J, Chen F, Epstein JA. 2000. Neural crest expression of Cre recombinase directed by the proximal Pax3 promoter in transgenic mice. Genesis 26:162-164.
15. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887.
16. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin D, Bressan GM, Piccolo S. 2003. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 100:3299-3304.
17. Molin DG, Poelmann RE, DeRuiter MC, Azhar M, Doetschman T, Gittenberger-de Groot AC. 2004. Transforming growth factor beta-SMAD2 signaling regulates aortic arch innervation and development. Circ Res 95:1109-1117.
18. Monteiro RM, Sousa Lopes SM, Korchynskyi O, ten Dijke P, Mummery CL. 2004. Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. J Cell Sci 117:4653-4663.
19. Ohnemus S, Kanzler B, Jerome-Majewska LA, Papaioannou VE, Boehm T, Mallo M. 2002. Aortic arch and pharyngeal phenotype in the absence of BMP-dependent neural crest in the mouse. Mech Dev 119:127-135.
20. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J. 2005. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844.
21. Schneider MD, Gaussin V, Lyons KM. 2003. Tempting fate: BMP signals for cardiac morphogenesis. Cytokine Growth Factor Rev 14:1-4.
22. Semenov M, Tamai K, He X. 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775.
23. van Bezooijen RL, Roelen BA, Visser A, Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.
24. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. 2005. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327.
25. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Lowik CW. 2006. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res, Epub ahead of print.
26. van der Eerden BC, Karperien M, Gevers EF, Lowik CW, Wit JM. 2000. Expression of Indian hedgehog, parathyroid hormone-related protein, and their receptors in the postnatal growth plate of the rat: evidence for a locally acting growth restraining feedback loop after birth. J Bone Miner Res 15:1045-1055.
27. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276.